Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Advertise | Contacts | Login 
  Users Online: 384 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
CASE REPORT
Year : 2020  |  Volume : 10  |  Issue : 2  |  Page : 83-88

Xanthoma disseminatum with extensive respiratory involvement effectively treated with cladribine: A case report


1 Department of pulmonary medicine, Al Assad University Hospital, Damascus, Syria
2 Department of General Surgery, Washington University in Saint Louis, Saint Louis, Missouri; Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio

Correspondence Address:
Shahed Tish
Department of General surgery, Resident PGY1 at Barnes Jewish Hospital; Washington University in Saint Louis, 1 Barnes Jewish Hospital Plaza, St. Louis, 63110-1003
Ohio
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ajm.ajm_177_19

Rights and Permissions

Xanthoma disseminatum (XD) is a rare and benign proliferative systemic disease that usually affects the skin and mucosal membranes with variable extent. Extensive systemic involvement can be associated with higher morbidity. There is paucity in the literature describing this rare pathological entity, and the ideal management remains controversial. In this article, we report our experience with cladribine in treating a case of XD. We documented the clinical and pathological manifestations of a 24-year-old woman who was initially diagnosed with rheumatoid arthritis. She presented to our institute with respiratory compromise and was found to have XD affecting skin, mucosal membranes, joints, and bone marrow. The patient received six cycles of cladribine for 6 months, during which she showed a remarkable response in relation to the respiratory lesions. Her hemoglobin also normalized and inflammatory markers gradually decreased to reach normal values. However, her skin lesions did not respond to treatment but no new lesions appeared. With our experience with cladribine, we believe that it could be a promising treatment option for XD. However, more work has to be conducted to determine the efficacy and safety in the long term.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1152    
    Printed67    
    Emailed0    
    PDF Downloaded149    
    Comments [Add]    

Recommend this journal